(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects.
about
Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogsCrystal structure of (S)-4-carbamoyl-4-(1,3-dioxo-isoindolin-2-yl)butanoic acid.Thalidomide and its derivatives: emerging from the wilderness.Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.Role of racemization in optically active drugs development.Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation.Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis.Enzymatic resolution and evaluation of enantiomers of cis-5'-hydroxythalidomide.Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors.Structural basis of thalidomide enantiomer binding to cereblon.LC-MS/MS and chiroptical spectroscopic analyses of multidimensional metabolic systems of chiral thalidomide and its derivatives.New probabilistic risk assessment of ethylhexyl methoxycinnamate: Comparing the genotoxic effects of trans- and cis-EHMC.Liquid chromatography with mass spectrometry enantioseparation of pomalidomide on cyclodextrin-bonded chiral stationary phases and the elucidation of the chiral recognition mechanisms by NMR spectroscopy and molecular modeling.Self-disproportionation of enantiomers of thalidomide and its fluorinated analogue via gravity-driven achiral chromatography: mechanistic rationale and implications.
P2860
Q34646752-96B79A9E-F13D-4F89-8045-506026C6953FQ34661167-F2B8B397-B7D3-465B-A683-A57BFB64CCDBQ35093456-9EC0B70F-2D33-4AB6-9E04-CC0C30D59B7FQ35107977-452B5317-4F8B-4F8F-B916-53D1C60F5A36Q36613990-03ECB8EE-0FD0-4F7A-9527-703A8DE5094DQ36773723-C8F3F2BF-31C7-48B6-905A-701DFE012D31Q41641598-17E5955F-37FB-4876-B30D-213DC9F2A845Q42544554-0DC3253C-CC14-4CE3-B6CE-BFB4378BEB83Q46637783-9DD4C977-97A0-477C-ACD3-DBA5A6CBDC08Q48167862-151E6906-1F85-45DA-87D7-F838A60EC338Q48191012-5EDE7925-6AAB-4E08-92A2-ACCBC237FB74Q48259058-022B0332-24AD-4FDC-90C8-33B6DC59253DQ49967134-B75AA01B-7B70-4488-8500-3A9A0B77F80BQ53059825-30307A37-F50A-4EE4-AE5D-2B9C4C0E79EEQ55020037-7BC0C805-1EB1-402E-9B20-FBDA388A45AB
P2860
(S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@ast
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@en
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@nl
type
label
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@ast
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@en
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@nl
prefLabel
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@ast
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@en
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@nl
P2093
P356
P1476
(S)-form of alpha-methyl-N(alp ...... ution of thalidomidal effects.
@en
P2093
Hashimoto Y
Nishimura K
P304
P356
10.1248/CPB.42.1157
P407
P577
1994-05-01T00:00:00Z